Counterparty decision · Counterparty & Relationship Check
Which relationship is evidenced, inferred or unresolved?
The buyer’s decision
Buyer: Life-science investors, device manufacturers, counsel and procurement. Decision trigger: FDA communication, study update, device recall or partner review.
Defined unit: Named entity and up to five related organisations or responsible entities identified from lawful records.
Research emphasis: Reconcile product identifiers, sponsor identity, clinical registry and regulator notices.. Records prioritised include FDA device database, ClinicalTrials.gov, product manufacturer registration.
Exactly what is investigated
- Confirm exact subject, legal identity and the limited research period
- Recover the agreed original records and record publication, effective and collection dates
- Which dated original FDA device database most directly proves the key assertion concerning counterparty & relationship check?
- Could trial not approval alter the proposed decision, and which record would disprove it?
- Test adverse or alternative evidence and distinguish absence of evidence from a negative finding
- Construct a traceable trial-source crosswalk for this decision
- Record the specific unavailable evidence and clarify what would change the conclusion
Deliverable and quality control
- Evidence-supported relationship diagram, mismatches, ownership questions and exposure caveats.
- trial-source crosswalk using traceable sources
- Dated and classified findings: supported, contradicted, unresolved or out of scope
- Human review of source-to-claim traceability and privacy considerations
- Concisely stated reliance limitations and decision-owner questions
Boundary, cost and acceptance
Commercial rule: Fixed scope and fixed fee agreed in writing, with human acceptance before work begins. A fee amount is not yet approved for publication. No automatic checkout, blanket monitoring commitment, performance guarantee or prepaid credits.
- No medical advice, efficacy certification or approval determination.
- Unlimited records, new jurisdictions, third-party licensed datasets and urgent handling unless contracted
- Final legal, accounting, medical, security, engineering, valuation or regulated sign-off
For a faster decision, commission the narrowest product that can resolve the immediate evidence question. Larger dossiers are optional and should follow a documented need.
Evidence starting points and what they do not prove
These databases and materials are starting points only. We do not claim that a named buyer, project, company or occurrence has been verified on this page.
- U.S. FDA device recall public API Official or industry source for use if relevant, not evidence of a named case
- US FDA clinical trials via ClinicalTrials.gov Official or industry source for use if relevant, not evidence of a named case
- openFDA status and data currency Official or industry source for use if relevant, not evidence of a named case
Defined evidence, not an unlimited research engagement
Decision-specific checks
- What is the authoritative product, trial and regulatory-record status?
- Independent contrary-source check and named source version/date
- Explicit not-observed / outside-mandate decision
What to provide
- Exact subject identifier and jurisdiction
- Decision date, quoted claim or document
- Permitted supporting evidence and known contrary claims
Illustrative delivery components
Supported-link diagram and unresolved identities and a source index stating record ID, issuer, effective date, read date and unresolved matters.
Professional reliance limit
No medical advice, efficacy certification or approval determination.
Illustrative specification only. No factual conclusion or cleared buyer has been represented. Written scope, fee and researcher acceptance are required.
Evidence before commitment · clearly bounded
A specific answer for a specific decision
Know what the evidence supports before the next step.
What the review checks
What you supply
A human-reviewed source and contradiction assessment. No general AI answer is accepted as independent evidence. Scope, actual source availability, exclusions, fixed fee and delivery date are agreed in writing before work begins.
Download illustrative PDF: Related-entity test | Aperture Research WorksThis specimen describes the method and possible deliverables. It is not a completed client investigation and contains no case findings.